Zhittya Genesis Medicine

Zhittya Genesis Medicine is a privately held American biotechnology company headquartered in Las Vegas, Nevada. It is focused on the development and commercialization of human FGF-1 (fibroblast growth factor 1), a naturally occurring protein that promotes angiogenesis — the growth of new blood vessels — and neurogenesis, the growth of new neurons. The company believes that FGF-1 can address the root cause of numerous diseases characterized by inadequate blood flow (ischemia), including coronary artery disease, stroke, diabetic foot ulcers, and vascular dementia, as well as neurodegenerative conditions such as Parkinson's disease and Alzheimer's disease. According to the company, its management has spent over 20 years and $150 million developing FGF-1. Since 1998, Daniel Montano, Viktoriya Tamlenova-Montano, and Dr. Jack Jacobs have worked to bring the drug to market. Zhittya has identified 19 disorders out of more than 75 human diseases linked to poor perfusion that it intends to target with FGF-1 therapy. The company is led by CEO Dan Montano, a former floor broker and investment banker, and President and Chief Science Officer Dr. Jack Jacobs, who has over 25 years of healthcare industry experience, including drug manufacturing oversight and clinical trial management. Zhittya Genesis Medicine operates as a private entity and does not disclose a parent company or stock listing.

Zhittya Genesis Medicine was founded in 1998 by Daniel Montano, Viktoriya Tamlenova-Montano, and Dr. Jack Jacobs. The company is based in Las Vegas, Nevada, and is dedicated to the development and commercialization of human FGF-1 (fibroblast growth factor 1), a naturally occurring growth factor discovered in the 1970s and extensively studied since. FGF-1 is known for its ability to promote angiogenesis — the growth of new blood vessels — and neurogenesis, the growth of new neurons. The founding team brought together expertise in finance and biotechnology. Daniel Montano, a former floor broker and investment banker who handled over 100 IPOs, left investment banking in 1998 to focus on advancing biotechnology breakthroughs. Dr. Jack Jacobs, with over 25 years in the healthcare industry and experience at Merck, joined as President and Chief Science Officer. Together, they have worked to bring FGF-1 to market. According to the company, its management has expended over 20 years and $150 million USD in developing FGF-1. Zhittya believes that FGF-1 can reverse the root causes of vascular diseases by reestablishing blood flow in ischemic tissues. The company has targeted 19 out of more than 75 human diseases resulting from a lack of blood flow or perfusion, including coronary artery disease, stroke, diabetic foot ulcers, and vascular dementia. It is also conducting research into neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. As of its public communications, Zhittya Genesis Medicine remains a private biotechnology company. It continues to pursue the clinical development and eventual commercialization of FGF-1 therapies.

• 1998

  Zhittya Genesis Medicine founded by Daniel Montano, Viktoriya Tamlenova-Montano, and Dr. Jack Jacobs.

• 1970

  FGF-1 discovered and subsequently extensively studied.

Regenerative medicine company targeting ischemic and neurodegenerative diseases through FGF-1 protein therapy.

• FGF-1

  A naturally occurring biological protein responsible for the growth of new blood vessels (angiogenesis) and can promote the growth of new neurons (neurogenesis). Zhittya is developing it as a therapeutic for diseases caused by lack of blood flow.

1. 1Zhittya Genesis Medicine Official Websitezgm.care
2. 2About Zhittya Genesis Medicine: Pioneering Regenerative Medicinezgm.care
3. 3Zhittya Genesis Medicine - Wikidatawikidata.org
4. 4Zhittya Genesis Medicine Signs $151.5 Million Biopharmaceutical Marketing Partnership Agreement with Regenerative Medicine of Latin Americabiospace.com